

1 **Title: Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for**  
2 **tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation**  
3 **of the 3HP Options Trial.**

4 **Authors:** Allan Musinguzi<sup>1¶</sup>, Joan R. Kasidi<sup>1¶</sup>, Jillian L. Kadota<sup>2</sup>, Fred Welishe<sup>1</sup>, Anne  
5 Nakitende<sup>1</sup>, Lydia Akello<sup>1</sup>, Jane Nakimuli<sup>1</sup>, Lynn T. Kunihiro<sup>3</sup>, Bishop Opira<sup>1</sup>, Yeonsoo Baik<sup>4</sup>,  
6 Devika Patel<sup>5,6</sup>, Amanda Sammann<sup>5,6</sup>, Christopher A. Berger<sup>2</sup>, H el ene E. Aschmann<sup>7</sup>, Payam  
7 Nahid<sup>2</sup>, Robert Belknap<sup>8</sup>, Moses R. Kanya<sup>1,9</sup>, Margaret A. Handley<sup>10</sup>, Patrick PJ Phillips<sup>2</sup>, Noah  
8 Kiwanuka<sup>11</sup>, Achilles Katamba<sup>3,12</sup>, David W. Dowdy<sup>3,13</sup>, Adithya Cattamanchi<sup>2,3,14</sup>, Fred C.  
9 Semitala<sup>1,9,15&\*</sup>, Anne R. Katahoire<sup>16&</sup>

10 **Author Affiliations:**

- 11 1. Infectious Diseases Research Collaboration, Kampala, Uganda
- 12 2. Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San  
13 Francisco General Hospital, University of California San Francisco, San Francisco, CA,  
14 USA
- 15 3. Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda
- 16 4. Department of International Health, Johns Hopkins Bloomberg School of Public Health,  
17 Baltimore, MD, USA
- 18 5. Department of Surgery, University of California San Francisco, San Francisco, CA, USA
- 19 6. The Better Lab, University of California, San Francisco, CA, USA
- 20 7. Department of Epidemiology and Biostatistics and Division of Pulmonary and Critical  
21 Care Medicine, University of California San Francisco, San Francisco, CA, USA

- 22 8. Denver Health and Hospital Authority and Division of Infectious Diseases, Department of  
23 Medicine, University of Colorado, Denver, CO, USA
- 24 9. Department of Medicine, School of Medicine, Makerere University College of Health  
25 Sciences, Kampala, Uganda
- 26 10. Department of Epidemiology and Biostatistics, University of California San Francisco,  
27 San Francisco, CA, USA
- 28 11. Department of Epidemiology and Biostatistics, School of Public Health, Makerere  
29 University College of Health Sciences, Kampala, Uganda
- 30 12. Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University  
31 College of Health Sciences, Kampala, Uganda
- 32 13. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,  
33 Baltimore, MD, USA
- 34 14. Division of Pulmonary Diseases and Critical Care Medicine, University of California  
35 Irvine, Irvine, CA, USA
- 36 15. Makerere University Joint AIDS Program, Kampala, Uganda
- 37 16. Child Health and Development Center, School of Medicine, Makerere University College  
38 of Health Sciences, Kampala, Uganda

39 \* Corresponding author

40 Email: [semitala@gmail.com](mailto:semitala@gmail.com) (FCS)

41 ¶ Contributed equally as first authors

42 & Contributed equally as senior authors

43 **Short title:** Qualitative evaluation of 3HP implementation for TB prevention among PLHIV

44 **Trial registration:** ClinicalTrials.gov (NCT03934931); Registered 2<sup>nd</sup> May 2019;

45 <https://clinicaltrials.gov/study/NCT03934931?id=NCT03934931&rank=1>

46 **Keywords:** Tuberculosis, Preventive therapy, People living with HIV, Healthcare providers,  
47 Implementation, RE-AIM framework, Qualitative methods, 3HP, barriers, facilitators

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

## 65 **Abstract:**

66 Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive  
67 treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence  
68 is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative  
69 assessment of 3HP delivery nested within the 3HP Options Trial, which compared three  
70 optimized strategies for delivering 3HP: facilitated directly observed therapy (DOT), facilitated  
71 self-administered therapy (SAT), and patient choice between facilitated DOT and facilitated SAT  
72 at the Mulago HIV/AIDS clinic in Kampala, Uganda. We conducted 72 in-depth interviews  
73 among PLHIV purposively selected to investigate factors influencing 3HP acceptance and  
74 completion. We conducted ten key informant interviews with healthcare providers (HCPs)  
75 involved in 3HP delivery to identify facilitators and barriers at the clinic level. We used post-trial  
76 3HP delivery data to assess sustainability. We conducted an inductive thematic analysis and  
77 aligned the emergent themes with the RE-AIM framework dimensions to report implementation  
78 outcomes. Understanding the need for TPT, once-weekly dosing, shorter duration, and  
79 perceived 3HP safety enhanced acceptance overall. Treatment monitoring by HCPs and  
80 reduced risk of HIV status disclosure enabled DOT acceptance. Dosing autonomy enabled SAT  
81 acceptance. Switching between DOT and SAT as required enabled acceptance for patient  
82 choice. Dosing reminders, reimbursement for clinical visits, and social support enabled 3HP  
83 completion; pill burden, side effects, and COVID-19-related treatment restrictions hindered  
84 completion. All HCPs were trained and participated in 3HP delivery with high fidelity. Training,  
85 care integration, and collaboration among HCPs enabled, whereas initial concerns about 3HP  
86 safety among HCPs delayed 3HP adoption and implementation. SAT was maintained post-trial;  
87 DOT was discontinued due to inadequate ongoing financial support beyond the study period.  
88 Facilitated delivery strategies made 3HP treatment convenient for PLHIV and were feasible and

89 implemented with high fidelity by HCPs. However, the costs of 3HP facilitation may limit wider  
90 scale-up.

## 91 **Introduction**

92 Scaling up short-course tuberculosis (TB) preventive treatment (TPT) regimens is key to  
93 achieving ambitious global targets to end TB, especially among people living with HIV (PLHIV)  
94 in high-burden settings (1, 2). Newer TPT regimens, including weekly isoniazid and rifapentine  
95 for three months (3HP), have well-documented advantages (higher tolerability and completion)  
96 over the traditional six to nine months regimen of daily isoniazid (isoniazid preventive therapy,  
97 IPT) (3, 4) and are recommended by the World Health Organization (WHO) (5). However, the  
98 best approach to delivering 3HP to PLHIV in high-burden TB/HIV settings remains unclear.  
99 Although effective (3, 6), 3HP delivery by directly observed therapy (DOT) may not be cost-  
100 effective in high-burden, low-income settings (7, 8). Self-administered therapy (SAT) overcomes  
101 most of the barriers associated with DOT but may be less effective in high-burden settings (9).  
102 Therefore, to identify the optimal approach to 3HP delivery for PLHIV in a high-burden TB/HIV  
103 setting, we conducted a pragmatic randomized implementation trial (3HP Options Trial) of 3HP  
104 delivery strategies (facilitated DOT, facilitated SAT, or providing an informed choice between  
105 facilitated SAT and DOT using a shared decision aid) among 1655 PLHIV (with equal participant  
106 allocation per delivery strategy) at a high volume, urban HIV clinic in Kampala, Uganda, from  
107 July 13, 2020 to July 8, 2022 (10). The facilitated 3HP delivery strategies were optimized to  
108 promote facilitators (fear of contracting TB, trust in healthcare providers, and perceived benefits  
109 of DOT and SAT) and overcome the important barriers (lack of knowledge about TB/TPT, pill  
110 burden, potential side effects of TPT, and the perceived difficulties of DOT and SAT) identified  
111 through formative qualitative research (11). The 3HP Options Trial demonstrated >90%  
112 acceptance and completion of 3HP for all three delivery strategies, with no significant

113 differences between strategies. Overall, <1% of trial participants experienced an adverse event  
114 requiring treatment discontinuation (12, 13).

115 Here, guided by the RE-AIM implementation science framework (14, 15), we conducted an  
116 explanatory qualitative evaluation (16) to understand the processes and contextual factors that  
117 influenced 3HP acceptance and completion overall and within each delivery strategy during the  
118 trial; the clinic-level facilitators and barriers to adoption of the facilitated 3HP delivery strategies;  
119 the implementation of 3HP under each delivery strategy; and the sustainability of 3HP delivery  
120 at the trial site. By focusing on the perspectives of PLHIV who were offered 3HP, healthcare  
121 providers (HCPs) who provided the services, and the clinical and socioeconomic context in  
122 which the services were provided, we aimed to examine factors likely to enable or hinder the  
123 integration of 3HP into policy and practice.

## 124 **Materials and Methods**

### 125 **Study design**

126 This was an explanatory qualitative study in which we evaluated the implementation of 3HP  
127 during the 3HP Options Trial (10) in Kampala, Uganda. We assessed the reach, effectiveness,  
128 adoption, implementation, and maintenance domains of the RE-AIM framework. Detailed  
129 descriptions of the RE-AIM framework, its dimensions, and its application to this study are  
130 shown in **Table 1**. We followed the Consolidated Criteria for Reporting Qualitative Research  
131 (COREQ) when writing this manuscript (17). This study was approved by the School of Public  
132 Health Research Ethics Committee at the Makerere University College of Health Sciences  
133 (Kampala, Uganda), the Uganda National Council for Science and Technology (Kampala,  
134 Uganda), and the University of California San Francisco Institutional Review Board (San  
135 Francisco, CA, USA).

**Table 1. The RE-AIM framework adapted to the evaluation of 3HP delivery in the 3HP Options Trial**

| <b>RE-AIM dimensions and operational definitions</b>  | <b>Indicators/nature of data</b>   | <b>Measurement and sources of data</b>  |
|---|--|---|
| <b>Reach</b>  |  |   |
| Reach refers to 3HP acceptance. <sup>1</sup>  | Facilitators and barriers to 3HP acceptance.   | IDIs with PLHIV.  |
| <b>Effectiveness</b>  |  |   |
| Effectiveness refers to 3HP treatment completion. <sup>2</sup>  | Facilitators and barriers to 3HP completion.   | IDIs with PLHIV.  |
| <b>Adoption</b>   |  |   |
| Adoption refers to the willingness of healthcare providers to integrate 3HP into routine TPT practices at the Mulago ISS clinic.  | Number of healthcare providers trained on 3HP Options Trial protocol.<br>Number of healthcare providers willing to participate in 3HP delivery.<br>Facilitators and barriers to adoption             | Attendance lists of healthcare provider training.<br>Review of patient weekly assessment and referral forms completed by healthcare providers at the clinic.<br>KIIs with healthcare providers at the clinic. |
| <b>Implementation</b>   |  |   |
| Implementation refers to fidelity to the various components of the 3HP delivery strategies as per the 3HP Options Trial protocol. | Number of planned activities implemented.<br>Adaptations made to the study protocol.<br>Facilitators and barriers to implementation.   | Review of the 3HP Options Trial activity log.<br>Observation during the intervention process.<br>KIIs with healthcare providers at the clinic.<br>IDIs with PLHIV.  |
| <b>Maintenance</b>  |  |   |
| Maintenance is the extent to which 3HP delivery was integrated into routine TPT practices, modified, and sustained at the clinic. | 3HP integration into the national HIV program.<br>3HP Options Trial treatment facilitation components and 3HP delivery strategies integrated into routine 3HP delivery and maintained at the clinic. | Dissemination of study findings in national 3HP planning meetings.<br>Post-3HP Options Trial observations of 3HP delivery at the clinic.  |

*3HP* weekly isoniazid-rifapentine for three months, *TPT* TB preventive treatment, *PLHIV* people living with HIV, *REDCap* web-based research database, *99DOTS* digital adherence technology, *IDI* in-depth interview, *ISS* immune suppression syndrome, *KII* key-informant interviews, *HIV* human immunodeficiency virus

1. 3HP acceptance refers to taking at least one dose.

2. 3HP completion refers to taking at least 11 of 12 doses within 16 weeks of treatment initiation.

136

## 137 Study setting

138 The research was conducted at the Mulago Immune Suppression Syndrome (ISS) clinic run by  
 139 the Makerere University Joint AIDS Program (MJAP) in Kampala, Uganda. This clinic is the  
 140 largest specialized outpatient HIV clinic in Uganda, providing comprehensive HIV/AIDS care  
 141 and treatment services to more than 16,000 clients at no cost. The clinic started offering IPT to

142 eligible PLHIV in 2017. However, 3HP was unavailable at the clinic through the national HIV  
143 program until July 2022.

## 144 **Implementation strategies**

145 The 3HP Options trial evaluated three pragmatic 3HP delivery strategies: facilitated DOT,  
146 facilitated SAT, and informed patient choice between facilitated DOT and facilitated SAT (with  
147 the help of a decision aid). Details of these strategies are described elsewhere (10). Briefly,  
148 each strategy included standardized pre-treatment counseling, streamlined clinic visits, dosing  
149 reminders via the 99DOTS digital adherence technology platform from Bengaluru, India (18),  
150 and transport reimbursement (~4-8 USD/visit) per clinic visit. DOT participants took all 12  
151 weekly 3HP doses under the direct observation of HCPs at the clinic. SAT participants were  
152 required to take doses one, six, and 12 under direct observation at the clinic. They were  
153 provided with a waterproof pill pack containing pre-packaged doses 2-5 and 7-11, along with a  
154 card insert that had a toll-free telephone number to confirm their weekly dosing from home.  
155 Participants in the informed patient choice strategy were given the option to switch between  
156 DOT and SAT as required during 3HP treatment. Prior to the recruitment of study participants,  
157 all HCPs at the clinic received training on delivering and managing 3HP treatment and  
158 addressing any adverse events. Side effects and adherence monitoring were done by HCPs  
159 during weekly clinic visits for DOT and via the 99DOTS platform for SAT.

## 160 **Study population**

161 We interviewed a subset of PLHIV and HCPs for the qualitative research. PLHIV were  
162 approached either in person during clinic visits or via telephone calls during the COVID-19  
163 pandemic. All PLHIV provided written informed consent to future selection for participation in in-  
164 depth interviews (IDIs) at enrollment in the main trial, and additional verbal consent was sought



165 for IDIs conducted over the telephone. We selected equal numbers of PLHIV per 3HP delivery  
166 strategy for inclusion in the IDIs based on age, sex, duration of antiretroviral therapy (ART), 3HP  
167 treatment outcome, and 99DOTS engagement. Given that we were studying a single-center  
168 homogeneous population, a maximum sample size of 17 IDIs per 3HP delivery strategy would  
169 have sufficed to achieve thematic saturation, according to studies of empirical data (19). Every  
170 three months, during the two years of participant recruitment for the main trial, we selected three  
171 PLHIV enrolled in that period, per delivery strategy, for a pre-determined sample size of 72 IDI  
172 participants (24/delivery strategy).

173 HCPs were selected for inclusion in key-informant interviews (KIIs) based on their cadres and  
174 active involvement in implementing the 3HP Options Trial at the clinic. HCPs were approached  
175 in person and provided written informed consent to participate. The number of HCPs directly  
176 involved in 3HP implementation determined the KII sample size.

## 177 **Data collection and management**

178 We conducted IDIs and KIIs between 27<sup>th</sup> November 2020 and 30<sup>th</sup> March 2022. We developed  
179 interview guides based on our research questions and pretested them with PLHIV and HCPs at  
180 the clinic. JRK, a trained female social science researcher who was not familiar with study  
181 participants, conducted all the interviews. Prior to each interview, JRK established rapport with  
182 the participant and shared interview objectives. Interviews were conducted in person at the  
183 clinic in a private area with only the participant and interviewer in the room. Due to local travel  
184 restrictions during the COVID-19 pandemic, interviews were conducted over the telephone while  
185 respecting participants' privacy. Each interview lasted 35-50 minutes. IDIs with PLHIV explored  
186 contextual and process factors that influenced 3HP acceptance and completion. We defined  
187 3HP acceptance as taking at least one dose and completion as taking at least 11 of 12 doses  
188 within 16 weeks of treatment initiation. We defined contextual factors as those related to the

189 settings where the PLHIV lived, worked, and within which 3HP implementation occurred. We  
190 defined process factors as those related to the 3HP TPT regimen and its delivery per the study  
191 protocol.

192 HCP interviews explored their perspectives on implementing 3HP in the clinic using the three  
193 delivery strategies. The interviews further explored changes made in the patient workflow in the  
194 clinic during the implementation of the 3HP delivery strategies. KIIs were conducted towards the  
195 end of participant recruitment in the main trial to facilitate a better evaluation of the study. We  
196 achieved data saturation based on meaning saturation for IDIs and KIIs when no new  
197 details/aspects were identified for the various emergent codes (20).

198 All interviews were audio-recorded and transcribed verbatim. Expert translation was used to  
199 convert Luganda transcripts to English. Prior to importing transcripts into NVivo V1.6.1 (21), we  
200 ensured their accuracy and anonymity.

201 Finally, we conducted post-trial observations of 3HP delivery at the clinic for 14 months  
202 (November 2022 to December 2023) to assess the continuity of the study interventions.

## 203 **Data analysis**

204 The analytical process was led by a doctoral-trained social and behavioral scientist employed as  
205 a Professor at Makerere University, Kampala (ARK, female). It involved ARK and JRK reading  
206 and re-reading transcripts and open-coding the data. Weekly reflection meetings with ARK,  
207 JRK, AM, and FCS involved discussions, questions, and reflections on the coding process,  
208 resulting in valuable feedback and consensus. This collaborative process achieved the final  
209 coding and theme development, which enhanced reflexivity and interpretative depth. The codes  
210 and themes generated through the inductive process were mapped onto the five dimensions of  
211 the RE-AIM framework (reach, effectiveness, adoption, implementation, and maintenance) (14,  
212 15, 22). Corresponding quotations were extracted from the transcripts. The “reach” dimension

213 was used to reflect 3HP acceptance, whereas the “effectiveness” dimension reflected  
214 completion. The “adoption,” “Implementation,” and “maintenance” dimensions were used to  
215 reflect adoption, implementation, and sustainability, respectively, of 3HP delivery strategy  
216 components. Both inductive and deductive thematic analyses were used to interpret the data,  
217 aligning the emergent themes to a pre-existing theoretical framework.

## 218 **Data validation and feedback to study participants and** 219 **stakeholders**

220 We held two validation meetings with HCPs at the clinic, shared our findings, and received  
221 feedback. We also shared the study results with PLHIV at the clinic during routine health  
222 education talks. HCPs and PLHIV confirmed that the findings resonated with their experiences.  
223 We shared our findings with the Ministry of Health in Uganda through the National TB and  
224 Leprosy Program's 3HP planning meetings before the HIV program roll-out of 3HP in Uganda.

## 225 **Results**

### 226 **Characteristics of interview participants**

227 Seventy-two PLHIV (24 per 3HP delivery strategy) participated in the IDIs. Of these, 42 (58%)  
228 were female, and the median age was 40 years (interquartile range [IQR]: 30.5-45). The median  
229 time on ART was 6.9 years (IQR: 1.9-11.3), and 17 (24%) reported prior TB disease. Ten  
230 healthcare providers participated in the KIIs. Of these, eight (80%) were male, and the median  
231 age was 31.5 years (IQR: 29-36). The duration in service at the current post ranged from six  
232 months to 17 years (median 4 years; IQR: 3-7).

### 233 **Reach**

## 234 **Facilitators of reach**

235 The high overall acceptance of 3HP treatment was attributed to three main factors. First,  
 236 following pre-treatment counseling, PLHIV perceived themselves as being at a high risk of  
 237 contracting TB. Second, the shorter duration and once-a-week 3HP dosing schedule were  
 238 convenient for them. Finally, PLHIV perceived 3HP to be safe and tolerable, which was  
 239 reinforced by positive feedback from both HIV peers and HCPs at the clinic. **Table 2**  
 240 summarizes the facilitators of reach reported by PLHIV, overall and within each 3HP delivery  
 241 strategy:

242 *“I didn’t fear, because at first, I had feared, but when I saw others going for it, others*  
 243 *were saying it doesn’t treat them badly, I said now for me why do I fear?” (Male*  
 244 *participant, Facilitated SAT).*

**Table 2. Facilitators of reach overall and within each 3HP delivery strategy**

| 3HP delivery strategy  | Facilitators  | Quote   |
|------------------------|---|---|
| <b>Overall</b>         | Acknowledgment of the significant risk of contracting TB by PLHIV | <i>Before, I had seen a man on (HIV) medication who had contracted TB from prison, I think he was released due to his worsening health condition, on reaching here he was told he had TB. He got so ill and I was scared of TB so much that when I heard there was prevention, I rushed to get it since prevention is better than cure and I had seen how much a TB patient suffered. (Female participant, Facilitated DOT)</i> |
|                        | The shorter duration and once-a-week 3HP dosing schedule          | <i>I had been informed before about it and I wanted initially to enroll for the 6-month dose (IPT), but I was demoralized with the length of the period and when I learned about the other option of the 3 months, then I reconsidered the later. (Male participant, Facilitated SAT)</i>   |
|                        | The perceived safety of 3HP                                       | <i>I didn’t fear, because at first, I had feared but when I saw others going for it, others were saying it doesn’t treat them badly, I said now for me why do I fear? (Male participant, Facilitated SAT)</i>   |
| <b>Facilitated DOT</b> | Easier access to healthcare providers at the clinic               | <i>The other advantage is that we get the opportunity to talk to the health workers about our progress in taking medicine and whether we have any challenges with taking the medicine. (Female participant, Facilitated DOT)</i>  |
|                        | Difficulty in self-supervising once-weekly dosing at home         | <i>I think taking from the clinic is more advantageous than taking from home. Sometimes when you take from home you can forget but if you take from the clinic you know that on such a day I will take from the clinic. (Male participant, Facilitated DOT)</i>   |
|                        | Fear of disclosing HIV status to household members                | <i>.... And also, there’s privacy here (clinic) unlike at home where people will start imagining you have HIV. Here everyone minds their business. (Male participant, Facilitated DOT)</i>  |
|                        | Convenience through residence or work                             | <i>I saw it convenient for me, to pass by the health center to take the medicine on my way to work. However, if I had kept it at home, I could easily forget it when rushing for work only to remember when I’ve gone but here, I could</i>   |

|                        |  |   |
|------------------------|--|---|
|                        | schedule   | <i>easily remember to pass by even when I'm in the taxi I just board off, take my medicine and proceed to work. Then, I knew I would always be reminded by medical personnel here if I hadn't come to take medicine whereas at home nobody would ask if I had taken medicine. (Female participant, Facilitated DOT).</i>  |
| <b>Facilitated SAT</b> | Autonomy and convenience                             | <i>I wanted to take the medicine from home, and the reason is because of time. In the morning hours, I normally have to attend to my business (purchasing fish that I sell to my clients). So, my morning hours are always busy, and I thought it wouldn't work well for me if I was required to be at the health facility at 9 am." (Female participant, Facilitated SAT).</i> |
| <b>Patient Choice</b>  | Ability to choose a convenient 3HP delivery strategy | <i>At first, I got it from the health facility but only for the first week then the second week it became difficult because of transport issues, I explained this to the health workers to allow me to take it from home because of the transport costs and I was allowed to take it from home. (Female participant, Patient Choice)</i>  |

3HP weekly isoniazid-rifapentine for three months, TB tuberculosis, PLHIV people living with HIV, DOT directly observed therapy, SAT self-administered therapy, Patient Choice between facilitated DOT & SAT arms, IPT daily isoniazid for six months, HIV human immunodeficiency virus

245

246 Most participants who received 3HP under DOT accepted treatment because DOT was better  
 247 aligned with their lifestyle and addressed their perceived barriers to treatment, including the fear  
 248 of accidentally disclosing their HIV status to significant others or other household members if  
 249 they had to take their medicines from home. This was especially true among young adults:

250 *"You see at home it would have been very difficult for me because I share (a room) with*  
 251 *a friend. The reason is that he would not have liked it maybe or he would have viewed it*  
 252 *negatively. The other thing is that it becomes difficult to hide." (Male participant, Patient*  
 253 *Choice).*

254 Furthermore, PLHIV for whom the clinic was nearby either through residence or work and those  
 255 who preferred the real-time, in-person reassurance of a health worker while taking their  
 256 medicines, either for fear of drug-related side effects or the inability to self-administer the once-  
 257 weekly 3HP dosing schedule, were more comfortable with DOT:

258 *"I saw it convenient to pass by the health center to take the medicine on my way to work.*  
 259 *However, if I had kept it at home, I could easily forget it when rushing for work only to*  
 260 *remember when I've gone but here, I could easily remember to pass by even when I'm*  
 261 *in the taxi I board off, take my medicine and proceed to work. Then, I knew I would*

262 *always be reminded by medical personnel here if I hadn't come to take medicine,*  
263 *whereas at home, nobody would ask if I had taken medicine.” (Female participant,*  
264 *Facilitated DOT).*

265 The convenience and autonomy associated with SAT were the strongest facilitators of treatment  
266 acceptance among PLHIV with busy work and daily life schedules:

267 *“That’s what I wanted because you may have gone for a trip and you find that it will*  
268 *coincide with that Wednesday or you are going on Tuesday it means you have to come*  
269 *on Tuesday now the days don’t connect but if you swallow from home when they give it*  
270 *to you even when you go on Wednesday you go with your medicine.” (Male participant,*  
271 *Facilitated SAT).*

272 One of the main reasons why patients in the informed patient choice group accepted treatment  
273 was because they were given the freedom to choose a delivery method that was convenient for  
274 them:

275 *“At first, I got it from the health facility but only for the first week, then the second week, it*  
276 *became difficult because of transport issues; I explained this to the health workers to*  
277 *allow me to take it from home because of the transport costs and I was allowed to take it*  
278 *from home.” (Female participant, Patient Choice).*

## 279 **Effectiveness**

### 280 ***Facilitators of effectiveness***

281 PLHIV reported that automated weekly dosing (SAT) or clinic appointment (DOT) reminders  
282 coordinated through the 99DOTS digital adherence technology platform helped ensure  
283 treatment completion across all delivery strategies. **Table 3** provides a summary of what

284 enabled and hindered treatment effectiveness as reported by participants, both overall and  
 285 within each 3HP delivery strategy:

286 *“I used to get a call on Monday reminding me to take my drugs. It was good and very*  
 287 *helpful because it reminded me to take my drugs. Anyone can forget.” (Male participant,*  
 288 *Facilitated SAT).*

**Table 3. Facilitators and barriers to effectiveness overall and within each 3HP delivery strategy**

| <b>3HP delivery strategy</b> | <b>Facilitators</b>   | <b>Barriers</b>   |
|------------------------------|---|---|
| <b>Overall</b>               | <b>Automated weekly dosing/clinic appointment reminders</b> - <i>It helped me because doctor, you may forget and may not know that tomorrow, I have to return but when they remind you by calling you, you get to know and say eh! Tomorrow I am returning to the hospital. Then you prepare and come. (Female participant, Facilitated DOT)</i>                          | <b>High pill burden at the beginning using loose pills of isoniazid and rifapentine (eleven pills per weekly dose)</b> - <i>Oh, the number yes, it was a challenge, they were so many that after taking them you could feel like vomiting. (Female participant, Patient Choice)</i>   |
|                              | <b>Reimbursement of travel costs</b> - <i>Another benefit was that we used to come with the hope that I would take my drugs from the clinic but there was something else that I would carry home. That also encouraged us. Personally, it encouraged me so much. (Female participant, Facilitated DOT)</i>  | <b>3HP-related side effects</b> - <i>After the first dose I felt sick until I decided to stop taking the medicine. (Female participant, Facilitated SAT)</i>  |
|                              | <b>Social support</b> - <i>The boss (work employer) first asked me to explain to him..... he said if that is it, okay it's good, every Wednesday when it reaches tell me so that if you have a safari to go I can cancel and another one goes or you look for another driver you give him and he goes then you wait for your day. (Male participant, Facilitated SAT)</i> | <b>COVID-19 pandemic-related treatment disruptions</b> - <i>I stopped during the COVID-19 lockdown because the situation was tough. I had to walk to pick up the medication (from the clinic) given that there were no transportation means.... And because I was not earning, I decided to go to the village. (Female participant, Patient Choice)</i> |
| <b>Facilitated SAT</b>       | <b>Packaging of 3HP medicines</b> - <i>"It's a good one (the pill pack) that it keeps the medication safe. You know, at home, you might have people touching here and there, so once they know that that thing is for your medication, nobody will tamper with it. So, it keeps the medication safe." (Male participant, Facilitated SAT).</i>                            |   |

*3HP weekly isoniazid-rifapentine for three months, DOT directly observed therapy, SAT self-administered therapy, Patient Choice between facilitated DOT & SAT arms*

289

290 Reimbursement of participants' travel costs associated with clinic visits also enabled adherence  
 291 and completion:



292 *“The most encouraging thing is that as we left, they would give us a transport refund. So,*  
293 *even if I did not have money on the day of picking medication, I would borrow from*  
294 *someone because I knew I would get a refund..... this helped me a lot.” (Female*  
295 *participant, Facilitated SAT).*

296 Across all delivery strategies, support from family, friends, and, in some cases, workmates  
297 motivated participants to complete treatment:

298 *“I told my mother and my sister. They told me it was a nice initiative, and they used to*  
299 *encourage me to take the medicines because they knew that I had HIV. My mother was*  
300 *ready to help me with transport if I ran short of it.” (Female participant, Facilitated DOT).*

301 Furthermore, among PLHIV who received 3HP under SAT, the labeling and packaging of their  
302 medicines enabled correct and timely dosing, as well as safe storage at home:

303 *“It’s a good one (the pill pack) that it keeps the medication safe. You know, at home, you*  
304 *might have people touching here and there, so once they know that that thing is for your*  
305 *medication, nobody will tamper with it. So, it keeps the medication safe.” (Male*  
306 *participant, Facilitated SAT).*

### 307 **Barriers to effectiveness**

308 Some PLHIV had difficulty completing 3HP treatment at the start of the study, before the switch  
309 to fixed-dose combination (FDC) pills, due to the high number of loose pills (eleven) in the  
310 weekly dose, in all delivery strategies:

311 *“Oh, the number (of pills), yes, it was a challenge; they were so many that after taking*  
312 *them you could feel like vomiting.” (Female participant, Patient Choice).*



313 In all delivery strategies, treatment-related side effects caused significant discomfort in some  
314 cases, affected participant livelihoods, and led to non-adherence and, ultimately, discontinuation  
315 of treatment:

316 *“It was all okay, but the side effects of the drug could not allow me to continue*  
317 *medication because I had decided to take my medicine, I realized I work for myself no*  
318 *one helps me so if I fail to work and all I do is to sleep, who will feed me? And that’s why*  
319 *I stopped taking it.” (Female participant, Facilitated SAT).*

320 The COVID-19 pandemic disrupted participants’ treatment plans across all delivery strategies.  
321 Community lockdowns resulted in restricted movement and increased transportation costs for  
322 clinic visits. Some PLHIV lost their livelihoods and had to relocate further away from the clinic,  
323 making it harder to attend clinic visits. Others feared contracting COVID-19 from the clinic and,  
324 therefore did not return for the scheduled visits:

325 *“Before the lockdown, I had taken the medicine for 6 weeks, and when the lockdown*  
326 *was announced, movement was impossible.” (Female participant, Facilitated DOT).*

## 327 **Adoption**

### 328 ***Facilitators of adoption***

329 Since 3HP was a new treatment, a training protocol was established to facilitate clinic staff  
330 education. The training was incorporated into the clinic's routine weekly continuing medical  
331 education (CME) sessions. A total of 87 clinic staff members were trained, including 14 HCPs  
332 who were directly involved in the delivery of 3HP according to the study protocol.

333 *“... The most important thing is the education. If there is continuous education, then*  
334 *things become easy. So, we had quite a number of CMEs before the real*

335 *implementation of 3HP and people got to know what 3HP is; what it involves; who can*  
336 *get 3HP and who cannot.” (Male HCP, interview 06)*

337 In addition to the general 3HP protocol training, the staff who directly participated in 3HP  
338 delivery were provided with job aids and standard operating procedures (SOPs) highlighting the  
339 management of common 3HP-related side effects.

340 *“We had training, and then they gave us job aids. We were given some books (3HP*  
341 *treatment protocols and standard operating procedures). These told us who qualifies for*  
342 *3HP, how to grade adverse drug reactions, how to manage the different adverse drug*  
343 *reactions, and how to fill out the ADR (adverse drug reaction) form. So, they took us*  
344 *through all those phases. Then still, study staff used to come during the introductory*  
345 *phases to guide us on what to do and what not to do because initially, we used to get*  
346 *scared and stop drugs even on a minor adverse drug reaction. So, they would come and*  
347 *guide us.” (Female HCP, interview 03).*

348 Three refresher training sessions were conducted during the 3HP treatment phase of the study  
349 to address ongoing implementation challenges and provide healthcare providers with updates  
350 about the project.

351 *“Midway, there was refresher training about the study, so I feel that should stay.... There*  
352 *were updates about the project. Some patients had developed side effects, but most of*  
353 *them were doing well with 3HP on a large scale. New information should always be*  
354 *passed on to the doctors to ensure they don't forget the information they learned earlier.”*  
355 *(Male HCP, interview 01).*

356

## 357 **Implementation**

### 358 ***Fidelity of implementing 3HP delivery***

359 3HP delivery was implemented as planned. However, there were two important protocol  
360 adaptations, including a switch to the 3HP fixed-dose combination and an increase in  
361 participants' transport reimbursement.

### 362 ***Switch to the 3HP fixed-dose combination***

363 When participant recruitment began on July 13th, 2020, the only form of the 3HP regimen  
364 available was loose pills containing rifapentine (150mg) and isoniazid (300mg). The weekly  
365 dose of 900mg required taking eleven pills, including two 25mg pyridoxine pills. However, in  
366 September 2020, Macleods Pharmaceuticals Limited released the 3HP FDC pills, which contain  
367 rifapentine and isoniazid in 300mg/300mg doses. On November 2nd, 2020, we began offering  
368 the 3HP-FDC pills after receiving the necessary regulatory approvals. With this new option,  
369 PLHIV no longer needed to take eleven pills per week, but only five. Some expressed difficulty  
370 in swallowing the large FDC pills, but most PLHIV appreciated the decrease in the number of  
371 pills.

372 *“It changed, the last dose changed.... they gave me one tablet that had a combination of*  
373 *very many. I took one tablet, it was big. I can't remember what the combination*  
374 *was.....but I know there was one tablet which they gave me which was big.... I prefer*  
375 *this one; the one tablet...eh, eh, eh, the other ones (initial eleven pills) were too many.”*  
376 *(Female participant, Facilitated SAT)*

### 377 ***Increase in participant travel cost reimbursement***

378 Due to COVID-19-related travel restrictions and the resulting rise in public transportation costs,  
379 we increased participant travel cost reimbursement from 4 to 8 USD to facilitate treatment

380 completion. This also enabled PLHIV, who had to miss work, to attend clinic visits to adhere to  
 381 and complete treatment.

382 *“I was not affected because they gave us transport. So, you would know that even if you*  
 383 *missed work, the money would help with transport and meals for the day depending on*  
 384 *the circumstances.... The first day, they gave me 15,000 (Uganda) shillings; the second*  
 385 *time, I got 15,000. The following days, when I came, they gave me 30,000 shillings. It*  
 386 *was enough. (Female participant, Facilitated DOT)*

### 387 **Facilitators of implementation**

388 The clinic had already been involved in preventing, diagnosing, and treating TB even before the  
 389 introduction of the 3HP treatment. This reportedly made the implementation process of 3HP  
 390 easier. PLHIV were already receiving daily IPT for six months, and there were already existing  
 391 SOPs in place for TB prevention, diagnosis, and treatment. Diagnostic tests were available for  
 392 those with suspected TB. Those who tested positive started treatment immediately. **Table 4**  
 393 summarizes barriers and facilitators to 3HP implementation at the clinic.

394 *“We began with Isoniazid in 2017 when the government began giving us doses. So, from*  
 395 *2018 to 2019, we ensured that all clients are put on isoniazid prophylaxis. The*  
 396 *challenge was the shortage of doses because the government would give us about*  
 397 *1,000 doses, and yet we have 6,000 clients so we prioritized who needs it more than the*  
 398 *other.” (Female HCP, interview 03).*

399

**Table 4. Facilitators and barriers to 3HP implementation at the Mulago ISS Clinic**

| Facilitators  | Barriers  |
|---|---|
| <p><b>The clinic was already involved in TB prevention -</b> Initially, we began with Isoniazid (IPT) in 2017; that is when the government began giving us other doses. So, since 2018-2019, we have ensured that all the clients are put on isoniazid prophylaxis but the challenge we had was the shortage of doses because the</p> | <p><b>Dealing with patients’ fears and concerns -</b> But still, you can’t fail to find those who resist it. Some people received biased information about this study. They come up with very many conspiracy theories about the study and such people fear to join and still, I always find time to talk to them and explain the truth about the</p> |

|  |  |
|--|--|
| <p>government would give us about 1,000 doses, and yet we have 6,000 clients so we prioritized who needs it more than the other. (Female HCP, interview 03).</p>   | <p>study. (Male HCP, interview 02)</p>   |
| <p><b>Closer collaboration</b> - There was a big gap between pharmacy and clinicians. They could make a phone call saying that this prescription is wrong but now, it has even drawn us closer because if a patient has an adverse drug reaction (ADR), the pharmacy team has to leave what they are doing to walk the patient this side (doctor's office), do what the doctor has told them so that you can document then you also walk the patient back. It has helped us draw closer. (Female HCP, interview 03)</p>  | <p><b>Healthcare providers were deficient in addressing 3HP-related adverse events</b> - Then still the study doctor used to come during the introductory phases to guide us on what to do and what not to do because initially, we used to get scared and stop drugs even on a minor adverse drug reaction. So, he would come and guide us. (Female HCP, interview 03).</p>   |
| <p><b>Integration of care</b> - We have a pharmacy that is dedicated to handling 3HP and other clients, and specifically, we handle it on a rotational basis. So, we get rotated. So, whoever is in that pharmacy for a given week or two weeks, handles 3HP clients as well as other clients like pediatrics, pregnant mothers, and the youths. (Male HCP, interview 08)</p>  | <p><b>Limited diagnostic facilities for adverse events at the clinic</b> - The liver function test was not full profile due to limited resources. We were doing AST and ALT only. We were not able to do bilirubin which is an important marker in liver functioning. (Male HCP, interview 01).</p>  |
| <p><b>Few 3HP-related adverse events</b> - Remember when you begin a new drug, like when we began DTG (dolutegravir-based antiretroviral therapy), patients are very suspicious even when they get a mosquito bite, they think it's an ADR (adverse drug reaction) and they come back running...they go down with time because with health education people stand up and give testimonies that I didn't react to the drug, you can also take it, I bought this one (medicine to treat an adverse event) and it was well, I continued and there was no effect so the ADRs keep on reducing. The people who come to report that they reacted, keep on reducing. (Female HCP, interview 03)</p> | <p><b>Interruptions in the clinic's routine patient flow</b> - If a patient is being taken for 3HP (screening and enrollment), they (study nurses) should document somewhere so that when that patient returns, they are prioritized (fast-tracked through their routine clinic appointment) because when the patient returns people (routine clinic staff) just make noise; now we've been here since morning, where have you been? You are fooling us! you are giving us a headache! It brings that kind of grudge between the clinician, nurse, and client. (Female HCP, interview 03).</p> |

3HP weekly isoniazid-rifampentine for three months, TB tuberculosis, DTG dolutegravir-based antiretroviral therapy, IPT isoniazid preventive therapy, ADR adverse drug reaction, AST aspartate aminotransferase, ALT alanine aminotransferase, 99DOTS digital adherence technology

400

401 Integrating 3HP delivery into the clinic's daily operations ensured accurate treatment. The clinic

402 streamlined pharmacy-only visits for stable PLHIV, who receive ART refills at a dedicated

403 pharmacy window. The follow-up visits for the treatment of the study participants were

404 conducted similarly. To reduce the workload at the pharmacy, an extra pharmacy technician

405 was hired and included in the team of pharmacy technicians. However, they were not

406 exclusively assigned to 3HP study operations. All pharmacy staff were trained to provide

407 services related to 3HP, and they were rotated every two weeks to ensure their skills were up-

408 to-date. As a result, HCPs did not experience an increased workload due to the introduction of

409 3HP as they initially anticipated.

410 *“I would get a maximum of three patients a day reporting 3HP-related side effects, and*  
411 *that is on a few days, but most of the days, I got one patient for 3HP. So, it wasn’t*  
412 *common that patients were presenting with side effects.” (Male HCP, interview 01).*

413 *“We have a pharmacy dedicated to handling 3HP and other clients; specifically, we*  
414 *handle it rotationally. So, we get rotated. So, whoever is in that pharmacy for a given*  
415 *week or two weeks handles 3HP clients and other clients like pediatrics and pregnant*  
416 *mothers, and the youths.” (Male HCP, interview 08).*

417 Concerns among HCPs regarding potential 3HP drug-related side effects were initially reported.  
418 However, the small number of serious adverse events helped to alleviate their fears.

419 *“Remember when you begin a new drug, like when we began DTG (dolutegravir),*  
420 *patients are very suspicious even when they get a mosquito bite, they think it’s an ADR*  
421 *(adverse drug reaction), and they come back running....they go down with time because*  
422 *with health education people stand up and give testimonies that I didn’t react to the drug,*  
423 *you can also take it, I bought this one (medicine to treat an adverse event), and it was*  
424 *well, I continued, and there was no effect so the ADRs keep on reducing. The people*  
425 *who come to report that they reacted (to the new medicine) keep on reducing.” (Female*  
426 *HCP, interview 03).*

427 3HP delivery reportedly promoted closer collaboration between clinicians (doctors and clinical  
428 officers) and pharmacy technicians. This teamwork enhanced fidelity to 3HP implementation:

429 *“...There was a big gap between pharmacy and clinicians. They could make a phone*  
430 *call saying that this prescription is wrong, but now, it has drawn us closer because if a*  
431 *patient has an adverse drug reaction, the pharmacy team has to leave what they are*  
432 *doing to walk the patient this side (doctor’s office), do what the doctor has told them so*

433 *that you can document and then walk the patient back. It has helped us draw closer.”*

434 *(Female HCP, interview 03).*

## 435 **Barriers to implementation**

436 PLHIV initially hesitated to accept 3HP due to safety concerns, but they consulted their trusted  
437 HCPs who eventually convinced them to try it.

438 *“You know, people are always worried about new things; initially, they have this*  
439 *anticipation that people want us dead. So, each time you bring something new, they are*  
440 *like, are they going to kill us? But you have to convince them that we are not going to kill*  
441 *them, all will be well, and then even some clinic staff had to take these drugs (3HP) to*  
442 *build more confidence in the clients. It helped us build more confidence and take the*  
443 *drugs better.” (Female HCP, interview 03).*

444 During the initial stage of participant recruitment, HCPs felt that they were not adequately  
445 equipped to manage adverse events associated with 3HP treatment for PLHIV. Therefore, they  
446 tended to be cautious and would discontinue 3HP treatment for PLHIV who experienced  
447 adverse events. However, as their confidence grew, clinicians became more willing to give  
448 PLHIV a chance to recover from adverse events and continue their treatment. The COVID-19  
449 pandemic further complicated adverse event management for PLHIV on 3HP treatment.

450 *“There was a season when we got a lot of suspected pulmonary embolism, it scared us*  
451 *a lot, and patients were told to do the cardiac ECHO and electrocardiogram (ECG) tests*  
452 *by themselves; they had to do the CT scan (Chest) by themselves, and they could not*  
453 *afford it. We lost interest somewhere, but when the cases went down, we picked up with*  
454 *time. I think it was due to COVID-19 because COVID-19 was causing those emboli, and*  
455 *since these people were on 3HP, we worried that maybe it is that 3HP that was causing*  
456 *the emboli.” (Female HCP, interview 03).*



457 During the enrolment process, patients were required to undergo certain tests that were not part  
458 of the clinic's routine procedures. This led to disruptions in the patient flow and caused delays.  
459 In addition, some patients experienced side effects that required further examination outside of  
460 the clinic. Unfortunately, this was often unaffordable for many patients. As a result, it made  
461 decision-making regarding the discontinuation of 3HP treatment more complicated. In some  
462 cases, decisions had to be made without proper diagnoses.

463 *“The liver function test was not full profile due to limited resources. We were doing AST*  
464 *and ALT only. We were not able to do bilirubin, which is an important marker in liver*  
465 *functioning.” (Male HCP, interview 01).*

466 Some clinicians were uncomfortable prioritizing study participants over other patients, especially  
467 when patients were waiting in the queue.

468 *“When a 3HP patient presented with a complication, there was a way that the doctor was*  
469 *supposed to dig deep to know more about the complication. This would make the doctor*  
470 *spend more time on the 3HP patient while holding up the queue for others because of*  
471 *the fast-tracking of 3HP patients. So other patients would not feel comfortable.” (Male*  
472 *HCP, interview 01).*

473

474

## 475 **Maintenance**

476 After the completion of the study, the national HIV program started providing 3HP treatment.  
477 Our research was presented to the national 3HP planning committee, which helped in the  
478 nationwide rollout of the treatment. HCPs continued to triage PLHIV for 3HP treatment and



479 offered standardized pre-treatment counseling to eligible individuals. However, there were some  
480 notable differences in the routine programmatic delivery of 3HP treatment compared to the trial.  
481 PLHIV receiving 3HP programmatically received all 12 doses of medication at once and were  
482 instructed to self-administer them weekly from home. They were asked to report any adverse  
483 events to clinic staff via telephone calls (not toll-free) or to return to the clinic for assistance if  
484 they experienced any adverse events within the 12 weeks. Interventions such as DOT, travel  
485 cost reimbursement, and digital adherence monitoring (99DOTS) were discontinued.

## 486 **Discussion**

487 In this qualitative evaluation, we found that facilitated delivery strategies were largely effective in  
488 overcoming barriers to 3HP acceptance and completion. Pre-treatment counseling enhanced  
489 patients' understanding of the need for TPT, and the less frequent dosing and shorter treatment  
490 duration of 3HP enhanced acceptance. Similarly, regardless of delivery method (SAT vs. DOT),  
491 weekly dosing reminders, reimbursement of participants' travel costs for clinic visits, and social  
492 support for PLHIV taking 3HP enhanced convenience and engagement, confirming that the  
493 facilitation components selected worked as intended and overcame the barriers to treatment  
494 completion for most participants. Among the minority who were unable to complete treatment,  
495 side effects and COVID-19 pandemic-related travel restrictions were key contributors. Although  
496 effective, the facilitation components other than pre-treatment counseling were not sustained  
497 following completion of the trial, largely because they (e.g. travel cost reimbursement, digital  
498 adherence monitoring with 99DOTS) require extra costs and logistics. Whether similar levels of  
499 treatment completion can be maintained without active facilitation requires further investigation.

500 Our findings confirm that features of the TPT regimen (safety profile, pill burden, treatment  
501 duration, and dosing frequency) are critical to acceptance, as has previously been reported  
502 elsewhere (23, 24), and that delivery strategies should be tailored to increase convenience,

503 provide flexibility based on changing circumstances, and ensure PLHIV feel connected to health  
504 workers. When appropriate facilitation components addressed these issues, both DOT and SAT  
505 were highly acceptable delivery strategies. Participants taking 3HP by DOT emphasized the  
506 benefits of having treatment closely monitored by a health worker and the lower risk of  
507 inadvertent HIV status disclosure with facility- vs. home-based treatment. Participants taking  
508 3HP by SAT found it helpful to have the ability to self-determine when and where to take  
509 treatment. This was particularly helpful for those who were employed or lived far from the clinic.  
510 In the patient choice strategy, some PLHIV found the ability to choose and switch between DOT  
511 and SAT critical based on their changing circumstances. Our study suggests that both DOT and  
512 SAT are viable options for 3HP delivery. The choice between the two methods depends on  
513 factors such as proximity to the health facility, ability to self-administer medication once a week,  
514 and living situation. Cost and convenience should also be considered when deciding which  
515 delivery method to use.

516 We found that high intervention adoption and implementation fidelity were made possible by  
517 training, close collaboration among HCPs, and the integration of the intervention into routine  
518 care. This reduced the disruption of routine practices in the clinic. Education prior to participant  
519 enrollment alleviated the initial concerns about 3HP safety and empowered HCP to address  
520 3HP-related adverse events. Similarly, Muddu et al. (2023) observed that HCP training and  
521 intervention integration into routine care enabled the adoption and implementation of an  
522 integrated HIV-hypertension intervention in the same setting (25); whereas Chisare et. al (2021)  
523 reported that HCP buy-in and strong collaborative capacity enabled 3HP adoption and  
524 implementation in four health care facilities in Zimbabwe in 2020 (26).

525 Our study had some limitations. First, the study was conducted in a single urban HIV clinic and  
526 involved participants who had high research literacy and HCPs who were already familiar with  
527 TPT implementation using IPT. This may have made it easier for participants to accept, adopt,

528 and implement 3HP and the results may only apply to similar HIV clinics. Second, we did not  
529 interview the four participants who did not initiate 3HP upon enrollment. As a result, we may  
530 have missed out on their unique perspectives on why they did not accept 3HP.

## 531 **Conclusions**

532 Using an established implementation science framework, we demonstrated that facilitated 3HP  
533 delivery is highly acceptable, effective, and feasible. To overcome initial concerns about the  
534 safety of 3HP among PLHIV and HCPs, counseling and training are essential. Additionally,  
535 active facilitation to minimize costs, increase convenience, and enhance connectedness to  
536 HCPs are critical for successful implementation. However, the expenses associated with 3HP  
537 facilitation may pose a challenge to wider scale-up, and further studies are required to assess  
538 the costs and efficiency of de-escalated facilitation strategies.

## 539 **Supporting information**

540 **S1 Checklist. Consolidated Criteria for Reporting Qualitative Research (COREQ)**

## 541 **Acknowledgments**

542 The authors are grateful to all the administration, staff, and clients at the Makerere University  
543 Joint AIDS Program (MJAP), Mulago ISS clinic for their time and participation in the study. We  
544 also thank the Infectious Diseases Research Collaboration (IDRC) for supporting the study.

## 545 **Authors' contributions**

546 **Conceptualization:** DP, CAB, PN, RB, MRK, MAH, PPJP, NK, AK, DWD, AC, FCS, ARK

547 **Data curation:** AM, JRK, JLK, FW, AN, LA, JN, LTK, BO, ARK

548 **Formal analysis:** AM, JRK, FCS, ARK

549 **Funding acquisition:** DWD, AC, FCS

550 **Investigation:** JRK

551 **Methodology:** AM, JRK, JLK, PN, MRK, MAH, PPJP, NK, AK, DWD, AC, FCS, ARK

552 **Project administration:** AM, JLK, PPJP, NK, AK, DWD, AC, FCS, ARK

553 **Supervision:** AM, JLK, DWD, AC, FCS, ARK

554 **Validation:** FCS, ARK

555 **Visualization:** AM, JRK, JLK, YB, AS, HEA, RB, MRK, MAH, DWD, AC, FCS, ARK

556 **Writing – original draft:** AM, JRK, JLK, DWD, AC, FCS, ARK

557 **Writing – review & editing:** AM, JRK, JLK, FW, AN, LA, JN, LTK, BO, YB, DP, AS, CAB, HEA,  
558 PN, RB, MRK, MAH, PPJP, NK, AK, DWD, AC, FCS, ARK

## 559 **References**

- 560 1. World Health Organization. , Global tuberculosis report 2023. Licence: CC BY-NC-SA 3.0  
561 IGO.2023.
- 562 2. Millington KA, White RG, Lipman M, McQuaid CF, Hauser J, Wooding V, et al. The 2023 UN high-  
563 level meeting on tuberculosis: renewing hope, momentum, and commitment to end tuberculosis.  
564 2024;12(1):10-3.
- 565 3. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly  
566 rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected  
567 persons. AIDS. 2016;30(10):1607-15.
- 568 4. Yanes-Lane M, Ortiz-Brizuela E, Campbell JR, Benedetti A, Churchyard G, Oxlade O, et al.  
569 Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-  
570 analysis. PLoS medicine. 2021;18(9):e1003738.
- 571 5. World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines  
572 for programmatic management. World Health Organization; 2018. Report No.: 9241550236.
- 573 6. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New Regimens to  
574 Prevent Tuberculosis in Adults with HIV Infection. New England Journal of Medicine. 2011;365(1):11-20.
- 575 7. Ferguson O, Jo Y, Pennington J, Johnson K, Chaisson RE, Churchyard G, et al. Cost-effectiveness  
576 of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine  
577 for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.  
578 2020;23(10):e25623.
- 579 8. Lai WA, Brethour K, D’Silva O, Chaisson RE, Zwering AA. Cost-effectiveness of 3-months  
580 isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic  
581 review. BMC Public Health. 2022;22(1):2292.
- 582 9. Belknap R, Holland D, Feng P-J, Millet J-P, Caylà JA, Martinson NA, et al. Self-administered Versus  
583 Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection.  
584 Annals of Internal Medicine. 2017;167(10):689-97.
- 585 10. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, et al. Protocol for the 3HP  
586 Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for  
587 short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implementation  
588 Science. 2020;15(1):65.

- 589 11. Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, et al. Acceptance and  
590 completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in  
591 Kampala, Uganda—patient and health worker perspectives. 2021;2(1):1-12.
- 592 12. Semitala FC, Kadota J, Musinguzi A, Nabunje J, Welishe F, Nakitende A, et al. Completion of  
593 Isoniazid-Rifapentine (3HP) for tuberculosis (TB) prevention among people living with HIV (PLHIV):  
594 interim analysis of the 3HP Options Trial. PLoS medicine. 2021.
- 595 13. Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, et al. Comparison of 3  
596 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention  
597 among people living with HIV in Uganda: A single-center randomized trial. PLoS medicine.  
598 2024;21(2):e1004356.
- 599 14. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion  
600 interventions: the RE-AIM framework. 1999;89(9):1322-7.
- 601 15. Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. RE-AIM Planning and  
602 Evaluation Framework: Adapting to New Science and Practice With a 20-Year Review. 2019;7.
- 603 16. Rogers P, Woolcock MJCFWPS. Process and Implementation Evaluations: A Primer. 2023.
- 604 17. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a  
605 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care.  
606 2007;19(6):349-57.
- 607 18. Cross A, Gupta N, Liu B, Nair V, Kumar A, Kuttan R, et al., editors. 99DOTS: a low-cost approach  
608 to monitoring and improving medication adherence. Proceedings of the Tenth International Conference  
609 on Information and Communication Technologies and Development; 2019: ACM.
- 610 19. Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: A systematic review of  
611 empirical tests. Social Science & Medicine. 2022;292:114523.
- 612 20. Hennink MM, Kaiser BN, Marconi VC. Code Saturation Versus Meaning Saturation: How Many  
613 Interviews Are Enough? Qualitative health research. 2017;27(4):591-608.
- 614 21. Dhakal K. NVivo. Journal of the Medical Library Association : JMLA. 2022;110(2):270-2.
- 615 22. Holtrop JS, Rabin BA, Glasgow RE. Qualitative approaches to use of the RE-AIM framework:  
616 rationale and methods. BMC Health Services Research. 2018;18(1):177.
- 617 23. Heyd A, Heffernan C, Storey K, Wild TC, Long R. Treating latent tuberculosis infection (LTBI) with  
618 isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment  
619 adherence: A qualitative descriptive study. PLOS Global Public Health. 2021;1(12):e0000017.
- 620 24. Yuen CM, Millones AK, Galea JT, Puma D, Jimenez J, Lecca L, et al. Toward patient-centered  
621 tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru. BMC Public  
622 Health. 2021;21(1):121.
- 623 25. Muddu M, Semitala FC, Kimera ID, Musimbaggo DJ, Mbuliro M, Ssenyonjo R, et al. Using the  
624 RE-AIM framework to evaluate the implementation and effectiveness of a WHO HEARTS-based  
625 intervention to integrate the management of hypertension into HIV care in Uganda: a process  
626 evaluation. Implementation Science Communications. 2023;4(1):102.
- 627 26. Dorothy TC, Rutendo BLZ-G, Charles C. Organizational Readiness for the Implementation of a  
628 Three-Month Short-Course TB Preventive Therapy Regimen (3HP) in Four Health Care Facilities in  
629 Zimbabwe in 2020: A Mixed Methods Study. medRxiv. 2021:2021.05.26.21256736.

630